CADL Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 41.60%

Insider Buying (Last 12 Months): $7,500,000.00

Insider Selling (Last 12 Months): $1,223,059.51

Candel Therapeutics Insider Trading History Chart

Candel Therapeutics Share Price & Price History

^$7.94

▼ -0.15 (-1.85%)

As of 03/13/2025 05:00 PM ET

Days: 30 | 90 | 365

Candel Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/15/2025	Francesca Barone	Insider	Sell	13,534	$7.22	$97,715.48	110,673
1/15/2025	Seshu Tyagarajan	CTO	Sell	14,322	$7.22	$103,404.84	96,790
1/8/2025	Francesca Barone	Insider	Sell	13,673	$8.22	$112,392.06	124,207
12/16/2024	Paul B Manning	Director	Buy	1,250,000	$6.00	$7,500,000.00	1,303,752
11/29/2024	Seshu Tyagarajan	CTO	Sell	20,392	$4.56	$92,987.52	125,657
11/29/2024	William Garrett Nichols	Insider	Sell	13,935	$4.56	$63,543.60	100,547
10/14/2024	Estuardo Aguilar-Cordova	Major Shareholder	Sell	15,000	$6.02	$90,300.00	929,873
10/11/2024	Estuardo Aguilar-Cordova	Major Shareholder	Sell	15,000	$6.05	$90,750.00	944,873
10/3/2024	Estuardo Aguilar-Cordova	Major Shareholder	Sell	1,800	$6.85	$12,330.00	959,873
7/17/2024	Charles Schoch	Insider	Sell	9,884	$6.47	$63,949.48	62,520
7/17/2024	Paul Peter Tak	CEO	Sell	22,528	$6.47	$145,756.16	330,735
7/17/2024	Seshu Tyagarajan	CTO	Sell	14,851	$6.47	$96,085.97	146,049
7/11/2024	Charles Schoch	Insider	Sell	8,897	$5.97	$53,115.09	72,404
7/11/2024	Paul Peter Tak	CEO	Sell	20,293	$5.97	$121,149.21	353,263
7/11/2024	Seshu Tyagarajan	CTO	Sell	13,330	$5.97	$79,580.10	160,900
12/8/2022	Francesca Barone	Insider	Buy	1,238	$1.61	$1,993.18	2,738
12/8/2022	Jason Amello	CFO	Buy	3,100	$1.69	$5,239.00	3,100
12/8/2022	Joseph C Papa	Director	Buy	3,014	$1.70	$5,123.80	3,014
12/8/2022	Paul Peter Tak	CEO	Buy	3,050	$1.70	$5,185.00	28,050
12/8/2022	Seshu Tyagarajan	CTO	Buy	3,000	$1.69	$5,070.00	3,000

See Full Table

SEC Filings (Institutional Ownership Changes) for Candel Therapeutics (NASDAQ:CADL)

13.93% of Candel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Candel Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Squarepoint Ops LLC	19,311	$0.17M	0.0%	+86.6%	0.059%
2/17/2025	Nuveen Asset Management LLC	68,226	$0.59M	0.0%	+3.0%	0.210%
2/17/2025	Maven Securities LTD	51,731	$0.45M	0.0%	N/A	0.159%
2/17/2025	Millennium Management LLC	31,626	$0.28M	0.0%	+130.6%	0.097%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	12,165	$0.11M	0.0%	+12.4%	0.037%
2/17/2025	Deutsche Bank AG	31,522	$0.27M	0.0%	+5,814.1%	0.097%
2/17/2025	Bridgeway Capital Management LLC	77,195	$0.67M	0.0%	-4.2%	0.238%
2/17/2025	Braidwell LP	1,600,000	$13.89M	0.4%	N/A	4.926%
2/17/2025	Baker BROS. Advisors LP	2,981,983	$25.88M	0.3%	N/A	9.181%
2/17/2025	Bank of America Corp DE	66,811	$0.58M	0.0%	+205.6%	0.206%
2/17/2025	BNP Paribas Financial Markets	3,434	$30K	0.0%	N/A	0.011%
2/17/2025	Acorn Capital Advisors LLC	1,939,644	$16.84M	9.2%	N/A	5.972%
2/14/2025	Northern Trust Corp	165,021	$1.43M	0.0%	+3.9%	0.508%
2/14/2025	Oxford Asset Management LLP	12,003	$0.10M	0.1%	N/A	0.037%
2/14/2025	Birchview Capital LP	60,000	$0.52M	0.4%	N/A	0.185%
2/14/2025	Heights Capital Management Inc.	30,000	$0.26M	0.1%	N/A	0.092%
2/14/2025	MetLife Investment Management LLC	13,773	$0.12M	0.0%	+9.7%	0.042%
2/13/2025	Portolan Capital Management LLC	753,745	$6.54M	0.4%	N/A	2.321%
2/13/2025	Barclays PLC	34,317	$0.30M	0.0%	+19.6%	0.106%
2/13/2025	Russell Investments Group Ltd.	3,753	$33K	0.0%	+75.1%	0.012%
2/13/2025	Wells Fargo & Company MN	10,122	$88K	0.0%	+63.6%	0.031%
2/12/2025	Geode Capital Management LLC	455,424	$3.95M	0.0%	+1.4%	1.402%
2/12/2025	JPMorgan Chase & Co.	10,426	$90K	0.0%	+15.2%	0.032%
2/11/2025	LPL Financial LLC	10,703	$93K	0.0%	N/A	0.033%
2/11/2025	Halter Ferguson Financial Inc.	681,334	$5.91M	2.4%	+123.7%	2.098%
2/10/2025	Commonwealth Equity Services LLC	41,098	$0.36M	0.0%	N/A	0.127%
2/6/2025	Charles Schwab Investment Management Inc.	52,190	$0.45M	0.0%	+11.6%	0.161%
2/5/2025	Oppenheimer & Co. Inc.	37,915	$0.33M	0.0%	N/A	0.117%
1/30/2025	Rhumbline Advisers	26,272	$0.23M	0.0%	+17.0%	0.081%
1/30/2025	Vontobel Holding Ltd.	19,000	$0.17M	0.0%	-13.6%	0.058%
1/15/2025	HB Wealth Management LLC	87,300	$0.70M	0.0%	+54.1%	0.269%
12/26/2024	JPMorgan Chase & Co.	9,051	$63K	0.0%	-53.2%	0.028%
11/19/2024	Barclays PLC	28,688	$0.20M	0.0%	+327.1%	0.088%
11/16/2024	Geode Capital Management LLC	448,997	$3.11M	0.0%	+12.8%	1.399%
11/15/2024	Barclays PLC	28,688	$0.20M	0.0%	+327.1%	0.089%
11/15/2024	MML Investors Services LLC	22,313	$0.16M	0.0%	-69.6%	0.070%
11/15/2024	State Street Corp	492,005	$3.41M	0.0%	+4.1%	1.534%
11/15/2024	Atom Investors LP	14,873	$0.10M	0.0%	N/A	0.046%
11/14/2024	MetLife Investment Management LLC	12,558	$87K	0.0%	N/A	0.039%
11/13/2024	FMR LLC	6,573	$46K	0.0%	N/A	0.020%
9/16/2024	Point72 DIFC Ltd	4,927	$31K	0.0%	N/A	0.017%
9/16/2024	Cubist Systematic Strategies LLC	26,121	$0.16M	0.0%	N/A	0.088%
8/14/2024	Cubist Systematic Strategies LLC	26,121	$0.16M	0.0%	N/A	0.088%
8/14/2024	Point72 DIFC Ltd	4,927	$31K	0.0%	N/A	0.017%
8/13/2024	Sands Capital Ventures LLC	405,837	$2.52M	0.8%	-50.0%	1.364%
8/9/2024	Renaissance Technologies LLC	20,600	$0.13M	0.0%	-63.8%	0.069%
8/1/2024	Rhumbline Advisers	22,985	$0.14M	0.0%	N/A	0.077%
7/26/2024	Bank of New York Mellon Corp	54,449	$0.34M	0.0%	N/A	0.183%
1/29/2024	Baystate Wealth Management LLC	76,910	$0.11M	0.0%	-21.0%	0.266%
5/10/2023	Resources Investment Advisors LLC.	25,428	$34K	0.0%	N/A	0.088%
4/25/2023	Baystate Wealth Management LLC	105,854	$0.14M	0.0%	N/A	0.366%
11/14/2022	Point72 Asset Management L.P.	403,131	$1.27M	0.0%	-45.7%	1.395%
5/6/2022	Empirical Asset Management LLC	12,000	$61K	0.1%	N/A	0.042%
4/26/2022	Kestra Advisory Services LLC	12,500	$64K	0.0%	N/A	0.044%
2/15/2022	Northpond Ventures LLC	1,935,215	$15.13M	5.3%	N/A	6.745%
2/15/2022	683 Capital Management LLC	40,929	$0.32M	0.0%	N/A	0.143%
11/15/2021	Caas Capital Management LP	50,000	$0.54M	0.0%	N/A	0.174%
11/15/2021	Franklin Resources Inc.	1,125,000	$12.20M	0.0%	N/A	3.921%
11/9/2021	BlackRock Inc.	22,326	$0.24M	0.0%	N/A	0.078%

Data available starting January 2016

See Full Table

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Today's Range

Now: $7.94

$7.80

$8.22

50 Day Range

MA: $8.22

$6.48

$12.21

52 Week Range

Now: $7.94

$1.34

$14.60

Volume

456,943 shs

Average Volume

2,650,654 shs

Market Capitalization

$257.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Candel Therapeutics?: Candel Therapeutics' top insider shareholders include:
Paul B Manning (Director)
Estuardo Aguilar-Cordova (Major Shareholder)
Paul Peter Tak (CEO)
Seshu Tyagarajan (CTO)
Francesca Barone (Insider)
William Garrett Nichols (Insider)
Charles Schoch (Insider)
Learn More about top insider investors at Candel Therapeutics.
Who are the major institutional investors of Candel Therapeutics?: Candel Therapeutics' top institutional shareholders include:
Baker BROS. Advisors LP — 9.18%
Acorn Capital Advisors LLC — 5.97%
Braidwell LP — 4.93%
Portolan Capital Management LLC — 2.32%
Halter Ferguson Financial Inc. — 2.10%
Geode Capital Management LLC — 1.40%
Learn More about top institutional investors of Candel Therapeutics stock.
Which major investors are selling Candel Therapeutics stock?: In the previous quarter, CADL stock was sold by these institutional investors:
Bridgeway Capital Management LLC
Vontobel Holding Ltd.
During the last year, company insiders that have sold Candel Therapeutics company stock include:
Paul B Manning (Director)
Estuardo Aguilar-Cordova (Major Shareholder)
Paul Peter Tak (CEO)
Seshu Tyagarajan (CTO)
Francesca Barone (Insider)
William Garrett Nichols (Insider)
Learn More investors selling Candel Therapeutics stock.
Which major investors are buying Candel Therapeutics stock?: Within the last quarter, CADL stock was purchased by institutional investors including:
Baker BROS. Advisors LP
Acorn Capital Advisors LLC
Braidwell LP
Portolan Capital Management LLC
Halter Ferguson Financial Inc.
Susquehanna International Group LLP
Rosalind Advisors Inc.
Citadel Advisors LLC